Addex Therapeutics Ltd
ADXNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 28, 2024 | H.C. Wainwright | Raghuram Selvaraju | $30.00(+185%) | $10.52 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | upgrade | Neutral →Buy | Jul 31, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 22, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2022 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 28, 2026 | $-1.49 | — | $12.3K | — |
| Jun 25, 2026 | $-1.53 | — | $9.9K | — |
| Apr 30, 2026 | $-1.94 | $-1.42 | $313.0K | $236.6K |
| Dec 4, 2025 | $-1.50 | — | $37.4K | $236.6K |
| Nov 10, 2025 | $-2.91 | $-1.42 | $45.2K | $236.6K |
| Jun 20, 2025 | $-1.33 | $-4.26 | — | $236.6K |
| Apr 7, 2025 | $-1.63 | $-1.42 | $1.7K | $150.0K |
| Nov 22, 2024 | $-2.77 | $-1.40 | $62.7K | $150.0K |
News
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 93,000,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.
Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation. Profitability This table compares Clene and Addex Therapeutics'
What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, and the program is being developed for schizophrenia. Addex said Neurosterix is its spin-out company and that Addex holds a
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical deve…
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development an…
Addex Therapeutics (NASDAQ: ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development spending on its GABAB positive allosteric modulator, or PAM, program lowered expenses. Chief Executive Officer Tim Dyer said the company also raised $2.8 million through
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”).
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C.